

Supplementary Online Material

Fowler NH, Chen G, Lim S, Manson S, Ma Q, Li FY. Treatment patterns and health care costs in commercially insured patients with follicular lymphoma. *JHEOR*. 2020;7(2):148-157.
doi:[10.36469/jheor.2020.16784](https://doi.org/10.36469/jheor.2020.16784)

Table S1. Recommended Treatment Regimens

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1. Recommended Treatment Regimens

List of NCCN Recommended Agents for Patients with FL	Drug Class	First-Line Regimens
Duvelisib	Kinase inhibitor	Fit Adults
Rituximab	Monoclonal antibody	Preferred regimens
Obinutuzumab	Cytolytic antibody	<ul style="list-style-type: none"> • Bendamustine and (obinutuzumab or rituximab)
Bendamustine	Chemotherapy	<ul style="list-style-type: none"> • CHOP and (obinutuzumab or rituximab)
Cyclophosphamide	Chemotherapy	<ul style="list-style-type: none"> • CVP and (obinutuzumab or rituximab)
Doxorubicin	Chemotherapy	<ul style="list-style-type: none"> • Lenalidomide and rituximab
Vincristine	Chemotherapy	Other regimens
Prednisone	Corticosteroid	<ul style="list-style-type: none"> • Rituximab
Lenalidomide	Immunomodulator	Frail Adults
Fludarabine	Chemotherapy	Preferred regimens
Mitoxantrone	Chemotherapy (antitumor antibiotic)	<ul style="list-style-type: none"> • Rituximab
Ofatumumab	Antibody	Other regimens
Ibritumomab tiuxetan	Radioimmunotherapy	<ul style="list-style-type: none"> • Chlorambucil and rituximab
Chlorambucil	Chemotherapy	<ul style="list-style-type: none"> • Chlorambucil
Idelalisib	Kinase inhibitor	<ul style="list-style-type: none"> • Cyclophosphamide
Copanlisib	Kinase inhibitor	<ul style="list-style-type: none"> • Ibritumomab tiuxetan

Abbreviations: NCCN, National Comprehensive Cancer Network.